These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9649134)

  • 1. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary.
    Orre M; Lotfi-Miri M; Mamers P; Rogers PA
    Br J Cancer; 1998 Jun; 77(12):2204-9. PubMed ID: 9649134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced vascular basement-membrane immunostaining in mucinous tumours of the ovary.
    Orre M; Rogers PA
    Int J Cancer; 1998 Apr; 79(2):139-43. PubMed ID: 9583727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary.
    Orre M; Rogers PA
    Int J Cancer; 1999 Apr; 84(2):101-8. PubMed ID: 10096239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer.
    da Silva BB; Lopes-Costa PV; dos Santos AR; de Sousa-Júnior EC; Alencar AP; Pires CG; Rosal MA
    Eur J Gynaecol Oncol; 2009; 30(3):285-8. PubMed ID: 19697622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the angiogenesis of benign and malignant ovarian tumors, demonstrated by analyses of color Doppler ultrasound, immunohistochemistry, and microvessel density.
    Emoto M; Iwasaki H; Mimura K; Kawarabayashi T; Kikuchi M
    Cancer; 1997 Sep; 80(5):899-907. PubMed ID: 9307190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
    Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Bösmüller H; Pfefferle V; Bittar Z; Scheble V; Horger M; Sipos B; Fend F
    Pathol Res Pract; 2018 Aug; 214(8):1136-1141. PubMed ID: 29935812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
    Saied EM; El-Etreby NM
    Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
    Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
    J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of prognostic factors for the extent of vascularity of serous ovarian cancer on the basis of CD34 antigen expression].
    Blok R; Blok K; Jeleń M; Gryboś M
    Ginekol Pol; 2004 Feb; 75(2):91-8. PubMed ID: 15108579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and Factor VIII.
    Norrby K; Ridell B
    APMIS; 2003 Apr; 111(4):483-9. PubMed ID: 12780523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Nestin and CD133 in serous ovarian carcinoma.
    Onisim A; Iancu M; Vlad C; Kubelac P; Fetica B; Fulop A; Achimas-Cadariu A; Achimas-Cadariu P
    J BUON; 2016; 21(5):1168-1175. PubMed ID: 27837619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
    Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
    Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microvessel quantification in primary colorectal carcinoma: an immunohistochemical study.
    Vermeulen PB; Verhoeven D; Fierens H; Hubens G; Goovaerts G; Van Marck E; De Bruijn EA; Van Oosterom AT; Dirix LY
    Br J Cancer; 1995 Feb; 71(2):340-3. PubMed ID: 7530985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
    Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
    Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
    Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
    J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of thymidine phosphorylase and vascular endothelial growth factor in epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor.
    Hata K; Fujiwaki R; Nakayama K; Maede Y; Fukumoto M; Miyazaki K
    Anticancer Res; 2000; 20(5C):3941-9. PubMed ID: 11268481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examining the technique of angiogenesis assessment in invasive breast cancer.
    Martin L; Green B; Renshaw C; Lowe D; Rudland P; Leinster SJ; Winstanley J
    Br J Cancer; 1997; 76(8):1046-54. PubMed ID: 9376265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.